Skip to main content

Table 1 Clinical and diagnostic findings in Vizsla polymyopathy

From: Clinical features of idiopathic inflammatory polymyopathy in the Hungarian Vizsla

Clinical and Diagnostic Findings in VIP Number of dogs from Group 1 % of total Group 1 dogs (24) Number of dogs from Group 2 % of total Group 2 (53) Total number of CASES with this clinical signs or had this diagnostic test out of total 77 dogs % of total cases (77)
Dysphagia (pharyngeal phase of deglutition) 20 83% 49 92% 69 90%
Drinking and eating difficulties (Oral phase of deglutition) 21 87% 48 91% 69 90%
Sialorrhea 21 87% 46 87% 67 87%
Masticatory muscle atrophy 20 83% 45 85% 65 84%
Regurgitation 19 79% 42 79% 61 79%
Trismus 3 12% 13 25% 16 21%
Masticatory myalgia 1 4% 8 15% 9 12%
Aspiration pneumonia 4 17% 13 25% 17 22%
Toxoplasma gondii serumantibody titre (tested for and negative) 14 58% 11 21% 25 32%
Neospora caninum serum antibody titre (tested for and negative) 15 62% 10 19% 25 32%
Elevated serum creatine kinase (>190 IU/L) 18 75% 23 43% 41 53%
Serum creatine kinase >1000 11 46% 14 26% 25 32%
Anti- 2 M antibody titre (Tested for and negative) 12 50% 17 32% 29 38%
Anti-acetylcholine receptor antibody titre (Tested for and negative) 16 67% 16 30% 32 42%
Electromyography (Performed and findings suggestive of myopathy) 15 62% 5 9% 20 26%
Electromyography (Performed and findings normal) 1 4% 2 4% 3 4%
Modality by which diagnosis Megaoesophagus was made Radiographs 8 33% 18 34% 26 34%
Barium 1 4% 9 17% 10 13%
Fluoroscopy 4 17% 8 15% 12 16%